Bellerophon Therapeutics Inc
NASDAQ:BLPH
Intrinsic Value
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. [ Read More ]
The intrinsic value of one
BLPH
stock under the Base Case scenario is
19.6055
USD.
Compared to the current market price of 0.0544 USD,
Bellerophon Therapeutics Inc
is
Undervalued by 100%.
Bellerophon Therapeutics Inc's market capitalization is 665.5k USD.
BLPH stock price is 0.0544 USD.
BLPH stock price (0.0544 USD) is 100% less than its Intrinsic Value (19.6055 USD).
BLPH. Open DCF Valuation
BLPH stock price (0.0544 USD) is 100% less than its Relative Value (19.6055 USD). Open Relative Valuation
BLPH.
BLPH's ROE (Return on Equity) has increased in the last 3 years from -143% to -139%, and is approaching profitability.
BLPH's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 10 577% to 1 391%.
BLPH's short-term assets (11m USD) exceed its short-term liabilties (6m USD).
BLPH's long-term assets (11m USD) exceed its long-term liabilties (6m USD).
BLPH has negative Operating Income for the last twelve months.
BLPH has negative Net Income for the last twelve months.
BLPH's ROE (Return on Equity) for the past 12 months is negative and is equal to -139%.
BLPH's ROIC (Return on Invested Capital) for the past 12 months is very high and is equal to 1 391%.
BLPH has negative Free Cash Flow for the last twelve months.
BLPH has negative three-year average ROE (Return on Equity): -95%. The company is not efficient at transforming stockholders' equity into net income.
BLPH has very high three-year average ROIC (Return on Invested Capital): 3 043%. The company is very efficient at using invested capital to generate operating income.
BLPH's D/E (Debt to Equity) is very low and is equal to 0.
BLPH's Altman Z-Score is very low and is equal to -34.9.
Fundamental Analysis
Bellerophon Therapeutics Inc
Balance Sheet Decomposition
Bellerophon Therapeutics Inc
| Current Assets | 11.2m |
| Cash & Short-Term Investments | 10.6m |
| Other Current Assets | 670k |
| Current Liabilities | 5.6m |
| Accounts Payable | 1.9m |
| Accrued Liabilities | 3.7m |
Earnings Waterfall
Bellerophon Therapeutics Inc
|
Revenue
|
5.6m
USD
|
|
Operating Expenses
|
-19.6m
USD
|
|
Operating Income
|
-14m
USD
|
|
Other Expenses
|
1.6m
USD
|
|
Net Income
|
-12.4m
USD
|
Free Cash Flow Analysis
Bellerophon Therapeutics Inc
What is Free Cash Flow?
BLPH Profitability Score
Profitability Due Diligence
Bellerophon Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
Score
Bellerophon Therapeutics Inc's profitability score is 38/100. The higher the profitability score, the more profitable the company is.
BLPH Solvency Score
Solvency Due Diligence
Bellerophon Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Score
Bellerophon Therapeutics Inc's solvency score is 51/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
BLPH Price Targets Summary
Bellerophon Therapeutics Inc
Ownership
BLPH Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
BLPH Price
Bellerophon Therapeutics Inc
| Average Annual Return | -34.95% |
| Standard Deviation of Annual Returns | 46.04% |
| Max Drawdown | -100% |
| Market Capitalization | 665.5k USD |
| Shares Outstanding | 12 230 000 |
| Percentage of Shares Shorted | 0.9% |
Company Profile
Bellerophon Therapeutics Inc
Country
Industry
Market Cap
Dividend Yield
Description
Bellerophon Therapeutics, Inc. focuses on developing products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company is headquartered in Warren, New Jersey and currently employs 20 full-time employees. The company went IPO on 2015-02-13. The firm is focused on developing products that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The focus of the Company’s clinical program is the continued development of its nitric oxide therapy for patients with pulmonary hypertension (PH) using its delivery system, INOpulse. The firm has three subsidiaries: Bellerophon BCM LLC, Bellerophon Pulse Technologies LLC and Bellerophon Services, Inc. The Company’s INOpulse program is an extension of the technology used in hospitals to deliver continuous flow inhaled nitric oxide. INOpulse program is built on scientific and technical developed for the therapeutic delivery of inhaled nitric oxide. The company is developing INOpulse for the treatment of patients with fibrotic interstitial lung disease (fILD) at a risk for pulmonary hypertension, which includes PH associated with idiopathic pulmonary fibrosis.
You don't have any saved screeners yet
